Skip to main content

Table 3 a and b Most frequent combinations of at least two and three substances

From: Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP

a.

   

Lithium

SSRI

9.2%

 

Valproic acid

SSRI

7.2

 

Lithium

Mirtazapine

5.8

 

Lithium

Venlafaxine

5.7

 

Quetiapine

SSRI

5.2

 

Quetiapine

Lithium

5.1

 

Lamotrigine

SSRI

4.9

 

Valproic acid

Venlafaxine

4.6

 

Valproic acid

Mirtazapine

4.5

 

Valproic acid

Lithium

4.1

 

Quetiapine

Lamotrigine

3.9

 

SSRI

Mirtazapine

3.8

 

Olanzapine

Lithium

3.7

 

Lamotrigine

Venlafaxine

3.7

 

Olanzapine

SSRI

3.6

 

Quetiapine

Valproic acid

3.4

 

Mirtazapine

Venlafaxine

3.4

 

Lamotrigine

Lithium

3.3

 

Valproic acid

Olanzapine

3.2

 

Lamotrigine

Mirtazapine

3.2

 

b.

   

SSRI

Quetiapine

Lithium

1.7%

SSRI

Quetiapine

Lamotrigine

1.3

SSRI

Mirtazapine

Lithium

1.2

SSRI

Mirtazapine

Valproic acid

1.2

SSRI

Mirtazapine

Venlafaxine

1.2

Lithium

Mirtazapine

Venlafaxine

1.2

SSRI

Olanzapine

Lithium

1.1

Lithium

Quetiapine

Venlafaxine

1.1

Lithium

Quetiapine

Lamotrigine

1.1

  1. Table 3a and b: Most frequent combinations (> 3% and > 1%, respectively) of at least two substances (Table 3a) and three substances (Table 3b) in percent (%) of all patients with bipolar depression (1994–2009).
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us